Additional GBM-derived factors such as interleukin 6 (IL-6) help recruit myeloid cells, prompt a shift in the immune response from inflammatory anti-tumor responses to anti-inflammatory and wound-healing type responses, reduce the ability of immune cells to effectively destroy tumor cells, and can lead to tissue remodeling to create a site of relative immune privilege and thereby preventing immunologic access to the tumor cells (14, 53, 54). Here, IL6 is linked to neoplasm.